// App-Quantinova.ai

774 : Cabozantinib, a multi-target receptor tyrosine kinase inhibitor, decreases tumor growth and angiogenesis in a patient-derived dedifferentiated liposarcoma xenograft

Researchers

Presenter

  • Haifu Li

Principal Investigators

  • Agnieszka Wozniak

  • Karel Van Den Bossche

  • Thomas Van Looy

  • Jasmien Wellens

  • Daphne Hompes

  • Dana Aftab

  • Maria Debiec-Rychter

  • Raf Sciot

  • Patrick Schoffski

Medical Centers

  • Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium

  • Department of Human Genetics, KU Leuven and University Hospitals, Leuven, Belgium

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

Locations

  • Belgium

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liposarcomas

Biomarkers

  • Microvessel density

  • Cluster of Differentiation 34

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Cabozantinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved